Evidence map›Paper›PMID 40136500›Full record

ReviewBiology2025

Decoding the Tumor-Associated Microbiota: From Origins to Nanomedicine Applications in Cancer Therapy.

Ruiqi Wang, Weizheng Li, Hongqian Cao, Lei Zhang

Abstract readReview
In one paragraph

Review in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Intratumoral Microbiome of Metastatic Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Emerging technologies and current challenges in intratumoral microbiota research.Frontiers in cellular and infection microbiology · 2025
    Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ruiqi WangMicrobiome-X, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.ORCID 0009-0007-8600-692X
Weizheng LiMicrobiome-X, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.ORCID 0000-0002-0154-9770
Hongqian CaoDepartment of Health Inspection and Quarantine, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.ORCID 0000-0003-3892-5562
Lei ZhangMicrobiome-X, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.

Funding

National Natural Science Foundation of China 82172320National Natural Science Foundation of China 82370785Shandong Provincial Natural Science Foundation ZR2024MH220the Future Program for Young Scholars of Shandong University 21320082364135
6 · The paper itself

Abstract

Growing evidence reveals that the tumor microbiome-comprising distinct microbial communities within neoplastic tissues-exerts a profound influence on cancer initiation, progression, and therapeutic response. These microbes actively reshape the tumor microenvironment (TME) through metabolite secretion, the modulation of immune pathways, and direct interactions with host cells, thereby affecting tumor biology and therapeutic outcomes. Despite substantial heterogeneity among cancer types, recent insights underscore the tumor microbiome's potential as both a diagnostic/prognostic biomarker and a targetable component for innovative treatments. In this review, we synthesize emerging knowledge on the mechanistic roles of tumor-associated microbiota in shaping the TME, with a focus on how these discoveries can guide novel therapeutic strategies. We further explore interdisciplinary advances, including the convergence of microbiomics and nanotechnology, to enhance drug delivery, circumvent resistance, and foster TME remodeling. By highlighting these cutting-edge developments, our review underscores the transformative potential of integrating tumor microbiome research into precision oncology and advancing more personalized cancer therapies.

Indexed as

cancer therapyimmune modulationnanotechnologyprecision medicinetumor-associated microbiotatumor microenvironment

Identifiers

PMID40136500
PMCPMC11940167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.